Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Quality Lowdown: New Valsartan Lessons, The 'White Hairs’ Who Remember Viracept

Executive Summary

Why EU challenged Huahai’s valsartan quick fix, how FDA is making a lesson of Huahai, and what happens when examples like the Viracept recalls fade from memory – it’s all in this week’s Lowdown. Plus how Atlas is purportedly assuring sterility on Carefree Highway, and what happened when Sun used out-of-specification exhibit batches.

You may also be interested in...

Pharmacy Urges US FDA To Disallow Levels Of DMF Solvent It Found In Valsartan

The saga of tainted valsartan has taken another turn with an online pharmacy that tests its medications before dispensing them finding yet another probable carcinogen in lots of the blood pressure medication from multiple manufacturers. The pharmacy filed a citizen petition asking the US FDA to tighten its globally harmonized limit for the residual solvent.

Don't Use Recycled Raw Materials In Valsartan And Other ARBs, US FDA Says

US FDA officials told manufacturers to beware of using reused solvents and catalysts to avoid carcinogenic impurities such as nitrosamines from leaching into valsartan and other ARBs used to treat high blood pressure. FDA has identified 40 nitrosamine-free ARBs to provide alternatives to patients and health care providers experiencing shortages caused by recent recalls of these products.

As Recalls Multiply, EU Agency Studies How To Rid Chinese Firm’s Valsartan API Of Probable Carcinogen

European authorities are examining how a manufacturing process change six years ago may have introduced a probable carcinogen into Zhejiang Huahai’s valsartan API that was only recently detected. They hope to learn how the firm could reduce or eliminate the impurity.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts